Table 3.
Side effects.
| Side effect | Overall prevalence with HDO (%) | Conley et al. 27 | Tollefson et al. 28 | Lindenmayer et al. 34 | Volavka et al. 29 | Conley et al. 30 | Chiu et al. 35 | Ermilov et al. 32 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HDO (25 mg fixed) |
Control | HDO (20.5 mg average) |
Control | HDO (40 mg max) |
HDO (30.4 mg average) | Control (Clozapine) | Control (Risperidone) | Control (Haloperidol) | HDO (50 mg fixed) |
Control | HDO (23.5 mg average) |
Control (N/A) |
HDO (30 mg fixed) |
Control | ||
| Dry mouth | 48 | 16/42 (38.1%) |
31/42 (73.8%) |
24/89 (27%) |
11/86 (12.8%) |
8/10 (80%) |
2/10 (20%) |
|||||||||
| Drowsiness/lethargy | 44 | 15/42 (35.7%) |
22/42 (52.4%) |
23/89 (25.8%) |
41/86 (47.7%) |
10/10 (100%) |
10/10 (100%) |
1/8 (12.5%) |
0/10 (0%) |
|||||||
| Nausea/vomiting | 36 | 5/42 (11.9%) |
5/42 (11.9%) |
5/90 (5.6%) |
15/90 (16.7%) |
9/10 (90%) |
6/10 (60%) |
|||||||||
| Headache | 33 | 12/42 (28.6%) |
8/42 (19%) |
10/90 (11.1%) |
5/90 (5.6%) |
6/10 (60%) |
4/10 (40%) |
|||||||||
| Dizziness | 27 | 6/42 (14.3%) |
7/42 (16.7%) |
6/89 (6.7%) |
26/86 (30.2%) |
6/10 (60%) |
6/10 (60%) |
|||||||||
| Constipation | 26 | 5/42 (11.9%) |
13/42 (31%) |
6/90 (6.7%) |
17/90 (18.9%) |
6/10 (60%) |
6/10 (60%) |
|||||||||
| Blurred vision | 25 | 4/42 (9.5%) |
5/42 (11.9%) |
4/10 (40%) |
0/10 (0%) |
|||||||||||
| Dyspepsia | 20 | 4/42 (9.5%) |
9/42 (21.4%) |
3/10 (30%) |
7/10 (70%) |
|||||||||||
| Orthostatic changes | 20 | 4/42 (9.5%) |
30/42 (71.4%) |
3/10 (30%) |
1/10 (10%) |
|||||||||||
| Increased weight/appetite | 18 | 6/90 (6.7%) |
6/90 (6.7%) |
4/10 (40%) |
5/10 (50%) |
3/51 (5.9%) | ||||||||||
| EPSEs/tardive dyskinesia | 15 | 12/42 (28.6%) |
21/42 (50%) |
5/89 (5.6%) |
0/86 (0%) |
5/39 (12.8%) |
5/40 (12.5%) |
13/41 (31.7%) |
1/8 (12.5%) |
0/10 (0%) |
||||||
| Increased salivation | 12 | 13/89 (14.6%) |
54/86 (62.8%) |
1/10 (10%) |
8/10 (80%) |
|||||||||||
| Insomnia | 11 | 6/42 (14.3%) |
2/42 (4.8%) |
7/90 (7.8%) |
3/90 (3.3%) |
6/51 (11.8%) | ||||||||||
| Agitation | 11 | 10/90 (11.1%) |
4/90 (4.4%) |
|||||||||||||
| Sweating | 10 | 8/89 (9%) |
19/86 (22.1%) |
1/10 (10%) |
5/10 (50%) |
|||||||||||
| Tachycardia | 9 | 1/42 (2.4%) |
7/42 (16.7%) |
5/90 (5.6%) |
5/90 (5.6%) |
2/10 (20%) |
0/10 (0%) |
|||||||||
| Increased blood glucose levels | 7 | 3/42 (7.1%) |
||||||||||||||
| Gait disturbances | 2 | 1/42 (2.4%) |
15/42 (35.7%) |
|||||||||||||
| Hypotonia | 2 | 2/89 (2.2%) |
9/86 (10.5%) |
|||||||||||||
| Fever | 1 | 1/90 (1.1%) |
5/90 (5.6%) |
|||||||||||||
| Reduced WCC | 1 | 1/90 (1.1%) |
5/90 (5.6%) |
3/40 (7.5%) |
2/41 (4.8%) |
1/37 (2.7%) |
EPSE, extrapyramidal side effect; HDO, high-dose olanzapine; WCC, white blood cell count.